home All News open_in_new Full Article

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

LEXINGTON, Mass. — Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France’s compassionate access (Accès compassionnel, or AAC) framework. The French National Agency of Medicines and Health Products Safety’s (ANSM) listings […]


today 5 d. ago attach_file Science

attach_file Other
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Sport
attach_file Sport
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Culture
attach_file Other
attach_file Science
attach_file Politics


ID: 4114480577
Add Watch Country

arrow_drop_down